What is the expected growth forecast for the PGD market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the PGD market?

Key drivers include advancing technology, rising infertility rates, and growing awareness of genetic disorders.

What challenges does the PGD market face?

Challenges include high costs, regulatory hurdles, and limited insurance coverage for PGD procedures.

Which regions are leading the PGD market?

North America and Europe are currently leading the market due to high adoption rates and advanced healthcare infrastructure.

Who are the top companies in the PGD market?

Top companies include Illumina, Thermo Fisher Scientific, and Agilent Technologies, offering a range of PGD products and services.

What future opportunities exist in the PGD market?

Future opportunities include expanding into emerging markets and developing new technologies to improve PGD outcomes.

How is technology impacting the PGD market?

Advances in next-generation sequencing and artificial intelligence are improving the accuracy and efficiency of PGD procedures.

What is the current regulatory landscape for the PGD market?

The regulatory landscape varies by region, with ongoing efforts to establish standardized guidelines and regulations for PGD practices.

What is the future outlook for the PGD market?

The future outlook is positive, with growing demand and advancing technologies expected to drive market growth and expansion.

Preimplantation Genetic Diagnosis (PGD) Market Comprehensive Report: 200+ Pages | 2026–2034

Preimplantation Genetic Diagnosis (PGD) by Type (Chromosomal Abnormalities, Gender Selection, X-linked Diseases, Aneuploidy, Single Gene Disorders, Others), by Application (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Preimplantation Genetic Diagnosis (PGD) Market Overview

The Preimplantation Genetic Diagnosis (PGD) market refers to the industry involved in the genetic testing of embryos prior to implantation. As a crucial aspect of modern reproductive medicine, the Preimplantation Genetic Diagnosis (PGD) market size is anticipated to experience significant growth, driven by advancements in genetic testing technologies and increasing awareness about genetic disorders. The growth outlook for the PGD market is positive, with a projected market forecast indicating a compound annual growth rate (CAGR) of around 10% from 2026 to 2033. This industry expansion is expected to be fueled by factors such as rising demand for genetic testing, advancements in technology, and growing awareness about the importance of genetic diagnosis. The scope of the PGD market encompasses various types of genetic testing, including genetic disorder diagnosis, chromosomal abnormality detection, and preimplantation genetic screening.

Loading chart…

The current Preimplantation Genetic Diagnosis (PGD) market size is estimated to be around $2.5 billion. The growth forecast for the market is positive, with a CAGR of around 10% from 2026 to 2033. Key forces shaping the industry include technology shifts, such as the development of next-generation sequencing technologies, regulations, such as the increasing regulation of genetic testing, and consumer behavior, such as the growing demand for genetic testing. The largest region for the PGD market is North America, while the fastest-growing region is expected to be Asia-Pacific. The Preimplantation Genetic Diagnosis (PGD) market is expected to experience significant growth in the coming years, driven by the increasing awareness about genetic disorders and the growing demand for genetic testing.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Thermo Fisher; Agilent Technologies; PerkinElmer; Coopersurgical; Abbott Laboratories; Natera; Takara Bio; Oxford Gene Technology; Yikon Genomics; Progenesis; Beijing Genomics Institute; Invitae; Invicta Genetics; Combimatrix; Genea Limited; Bioarray; Quest Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Preimplantation Genetic Diagnosis (PGD) market is poised for significant growth, driven by increasing awareness of genetic disorders and advancements in reproductive technology. The Preimplantation Genetic Diagnosis (PGD) market size is expected to expand rapidly, with a promising growth forecast.

Growth Drivers2 items

Advances in genetic testing technology, enabling more accurate and efficient diagnosis of genetic disorders, are driving the adoption of PGD services, thereby contributing to the growth of the Preimplantation Genetic Diagnosis (PGD) market.

Increasing awareness of genetic disorders and their impact on families, coupled with growing demand for family planning and reproductive health services, is fueling the demand for PGD, influencing the growth forecast of the market.

Restraints2 items

High costs associated with PGD procedures, including genetic testing and in vitro fertilization (IVF), are limiting access to these services, particularly in low- and middle-income countries, affecting the Preimplantation Genetic Diagnosis (PGD) market size.

Stringent regulatory frameworks and ethical concerns surrounding PGD, such as the potential for sex selection and genetic modification, are hindering the growth of the Preimplantation Genetic Diagnosis (PGD) market, with regulatory bodies closely monitoring industry developments.

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth opportunities for PGD service providers, driven by increasing demand for reproductive health services and growing awareness of genetic disorders, which is expected to impact the Preimplantation Genetic Diagnosis (PGD) market size.

Advances in _next-generation sequencing_ and other genetic testing technologies are creating new opportunities for PGD service providers to offer more comprehensive and accurate genetic testing services, influencing the growth forecast of the market.

Challenges2 items

The Preimplantation Genetic Diagnosis (PGD) market faces significant competition from other reproductive health services, such as prenatal testing and genetic counseling, which can divert demand away from PGD services, affecting the market's growth forecast.

PGD service providers must navigate complex and evolving regulatory landscapes, ensuring compliance with changing regulations and guidelines, while also addressing ethical concerns and societal attitudes towards PGD, to maintain a strong position in the Preimplantation Genetic Diagnosis (PGD) market.

Market Segmentation

Loading chart…

The Preimplantation Genetic Diagnosis (PGD) segmentation by type includes various subtypes that contribute to the overall market size. This segment is crucial in understanding the different technologies used in PGD, such as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR). Each subtype has its own set of applications and advantages, making it essential to analyze them separately to determine their market share and growth prospects.

The application segment of the Preimplantation Genetic Diagnosis (PGD) market is further divided into subtypes such as anembryonic, monogenic, and chromosomal abnormalities. This segmentation helps in understanding the different uses of PGD in identifying genetic disorders and selecting healthy embryos for implantation. By analyzing the market size and growth rate of each subtype, stakeholders can identify areas of opportunity and make informed decisions about investments and resource allocation.

Preimplantation Genetic Diagnosis (PGD) Segmentation Breakdown11 items

Type

Chromosomal Abnormalities

Gender Selection

X-linked Diseases

Aneuploidy

Single Gene Disorders

Others

Application

Maternity Centers & Fertility Clinics

Hospitals, Diagnostic Labs, and Service Providers

Research Laboratories & Academic Institutes

Regional Insights

Loading chart…

The Preimplantation Genetic Diagnosis (PGD) market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of PGD technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - high ecosystem maturity, increasing demographics of individuals seeking genetic testing, and favorable policies; Europe - growing awareness of genetic disorders, advancements in infrastructure, and supportive regulations; Asia Pacific - large demographics, rising income levels, and government initiatives to promote genetic testing; Latin America - improving infrastructure, increasing adoption of genetic testing, and growing demand for PGD services; Middle East & Africa - growing awareness of genetic disorders, rising income levels, and investments in healthcare infrastructure.

The regional forecast indicates that the Asia Pacific region will experience the highest growth rate, driven by the aforementioned factors. The Preimplantation Genetic Diagnosis (PGD) market growth in this region is expected to be fueled by the increasing demand for genetic testing and counseling services, particularly in countries such as China and India.

Competitive Landscape

The Preimplantation Genetic Diagnosis (PGD) market is moderately consolidated, driven by a mix of global players and local companies. The Preimplantation Genetic Diagnosis (PGD) competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players' strategies include:

Illumina: regional expansion

Thermo Fisher: innovation pipeline

Agilent Technologies: premium pricing

PerkinElmer: OEM tie-ups

Coopersurgical: local manufacturing

Abbott Laboratories: vertical integration

Key Preimplantation Genetic Diagnosis (PGD) Companies18 items

Illumina

Thermo Fisher

Agilent Technologies

PerkinElmer

Coopersurgical

Abbott Laboratories

Natera

Takara Bio

Oxford Gene Technology

Yikon Genomics

Progenesis

Beijing Genomics Institute

Invitae

Invicta Genetics

Combimatrix

Genea Limited

Bioarray

Quest Diagnostics

Market Ecosystem

The Preimplantation Genetic Diagnosis (PGD) ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three tiers: upstream, where raw materials and components are sourced; midstream, where technology providers and system integrators create value; and downstream, where channels and end users capture value. Understanding the PGD ecosystem requires a thorough value chain analysis, as it reveals how different participants interact and influence one another.

Raw material suppliers — provide genetic testing kits

Technology providers — develop genetic diagnostic tools

OEMs/manufacturers — produce PGD equipment

System integrators — configure PGD systems for clinics

Distributors/channel partners — supply PGD systems to clinics

Service providers — offer training and after-sales support

Regulators/standards bodies — set guidelines for PGD practices

In the PGD ecosystem, control points are primarily held by regulators and standards bodies, as they influence the adoption of PGD technologies through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of genetic testing kits, and standards, which can vary by region. Switching costs are relatively high due to the specialized nature of PGD equipment and the need for interoperability. As a result, partnerships between technology providers and system integrators are crucial for ensuring seamless integration and support. The PGD ecosystem differs by region, with varying levels of regulatory oversight and reimbursement policies affecting the demand for PGD services.

Recent Industry Insights

The Preimplantation Genetic Diagnosis (PGD) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between leading genetic testing companies and fertility clinics have expanded the reach of PGD services. Notably, the acquisition of a prominent genetic testing firm by a major healthcare company has strengthened the market position of the latter. Furthermore, the launch of advanced next-generation sequencing technologies has improved the accuracy and efficiency of PGD procedures. Regulatory changes, such as the updated guidelines for PGD by the American Society for Reproductive Medicine, have also had a profound impact on the industry. In addition, there has been a notable shift in consumer trends, with an increasing number of individuals opting for PGD to detect genetic disorders. Funding rounds and expansions by key players have also contributed to the growth of the PGD market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Preimplantation Genetic Diagnosis (PGD) market outlook. The market exhibits high attractiveness due to the growing demand for genetic testing and the increasing awareness of genetic disorders. The competitive intensity is moderate, with key players focusing on innovative technologies and strategic partnerships. The long-term outlook is positive, driven by advancements in genetic sequencing and editing technologies.

The innovation landscape is evolving rapidly, with emerging technologies such as next-generation sequencing and CRISPR gene editing. The demand-supply balance is favorable, with a steady increase in demand for PGD services. However, key risk factors include regulatory uncertainty and ethical concerns surrounding genetic testing. Overall, the Preimplantation Genetic Diagnosis (PGD) market outlook is promising, with opportunities for growth and innovation in the coming years.

11 items

1. Executive Summary

2. Preimplantation Genetic Diagnosis (PGD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preimplantation Genetic Diagnosis (PGD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Chromosomal Abnormalities

6.1.2. Gender Selection

6.1.3. X-linked Diseases

6.1.4. Aneuploidy

6.1.5. Single Gene Disorders

6.1.6. Others

6.2. Global Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Maternity Centers & Fertility Clinics

6.2.2. Hospitals, Diagnostic Labs, and Service Providers

6.2.3. Research Laboratories & Academic Institutes

6.3. Global Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Preimplantation Genetic Diagnosis (PGD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preimplantation Genetic Diagnosis (PGD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Preimplantation Genetic Diagnosis (PGD) Market Competition by Key Manufacturers

8.1. Global Preimplantation Genetic Diagnosis (PGD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Preimplantation Genetic Diagnosis (PGD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Illumina

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. PerkinElmer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Coopersurgical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abbott Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Natera

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Takara Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Oxford Gene Technology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Yikon Genomics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Progenesis

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Beijing Genomics Institute

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Invitae

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Invicta Genetics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Combimatrix

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Genea Limited

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Bioarray

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Quest Diagnostics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preimplantation Genetic Diagnosis (PGD) Market

Figure 4: Global Preimplantation Genetic Diagnosis (PGD) Market: Drivers

Figure 5: Global Preimplantation Genetic Diagnosis (PGD) Market: Challenges

Figure 6: Global Preimplantation Genetic Diagnosis (PGD) Market: Trends

Figure 7: Global Preimplantation Genetic Diagnosis (PGD) Market: Opportunity

Figure 8: Global Preimplantation Genetic Diagnosis (PGD) Market: Restraint

Figure 9: Global Preimplantation Genetic Diagnosis (PGD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Preimplantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 15: Global Preimplantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Preimplantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 23: Global Preimplantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Preimplantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Preimplantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Preimplantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Preimplantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 10: Global Preimplantation Genetic Diagnosis (PGD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Preimplantation Genetic Diagnosis (PGD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Preimplantation Genetic Diagnosis (PGD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Illumina Basic Information And Sales Area

Table 31: Illumina. Products Portfolio

Table 32: Thermo Fisher Basic Information And Sales Area

Table 33: Thermo Fisher. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: PerkinElmer Basic Information And Sales Area

Table 37: PerkinElmer. Products Portfolio

Table 38: Coopersurgical Basic Information And Sales Area

Table 39: Coopersurgical. Products Portfolio

Table 40: Abbott Laboratories Basic Information And Sales Area

Table 41: Abbott Laboratories. Products Portfolio

Table 42: Natera Basic Information And Sales Area

Table 43: Natera. Products Portfolio

Table 44: Takara Bio Basic Information And Sales Area

Table 45: Takara Bio. Products Portfolio

Table 46: Oxford Gene Technology Basic Information And Sales Area

Table 47: Oxford Gene Technology. Products Portfolio

Table 48: Yikon Genomics Basic Information And Sales Area

Table 49: Yikon Genomics. Products Portfolio

Table 50: Progenesis Basic Information And Sales Area

Table 51: Progenesis. Products Portfolio

Table 52: Beijing Genomics Institute Basic Information And Sales Area

Table 53: Beijing Genomics Institute. Products Portfolio

Table 54: Invitae Basic Information And Sales Area

Table 55: Invitae. Products Portfolio

Table 56: Invicta Genetics Basic Information And Sales Area

Table 57: Invicta Genetics. Products Portfolio

Table 58: Combimatrix Basic Information And Sales Area

Table 59: Combimatrix. Products Portfolio

Table 60: Genea Limited Basic Information And Sales Area

Table 61: Genea Limited. Products Portfolio

Table 62: Bioarray Basic Information And Sales Area

Table 63: Bioarray. Products Portfolio

Table 64: Quest Diagnostics Basic Information And Sales Area

Table 65: Quest Diagnostics. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Preimplantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 71: Global Preimplantation Genetic Diagnosis (PGD) Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Type

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Preimplantation Genetic Diagnosis (PGD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Thermo Fisher; Agilent Technologies; PerkinElmer; Coopersurgical; Abbott Laboratories; Natera; Takara Bio; Oxford Gene Technology; Yikon Genomics; Progenesis; Beijing Genomics Institute; Invitae; Invicta Genetics; Combimatrix; Genea Limited; Bioarray; Quest Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Preimplantation Genetic Diagnosis (PGD) Segmentation Breakdown11 items

Type

Chromosomal Abnormalities

Gender Selection

X-linked Diseases

Aneuploidy

Single Gene Disorders

Others

Application

Maternity Centers & Fertility Clinics

Hospitals, Diagnostic Labs, and Service Providers

Research Laboratories & Academic Institutes

Regional Insights

Loading chart…

Competitive Landscape

Illumina: regional expansion

Thermo Fisher: innovation pipeline

Agilent Technologies: premium pricing

PerkinElmer: OEM tie-ups

Coopersurgical: local manufacturing

Abbott Laboratories: vertical integration

Key Preimplantation Genetic Diagnosis (PGD) Companies18 items

Illumina

Thermo Fisher

Agilent Technologies

PerkinElmer

Coopersurgical

Abbott Laboratories

Natera

Takara Bio

Oxford Gene Technology

Yikon Genomics

Progenesis

Beijing Genomics Institute

Invitae

Invicta Genetics

Combimatrix

Genea Limited

Bioarray

Quest Diagnostics

Market Ecosystem

Raw material suppliers — provide genetic testing kits

Technology providers — develop genetic diagnostic tools

OEMs/manufacturers — produce PGD equipment

System integrators — configure PGD systems for clinics

Distributors/channel partners — supply PGD systems to clinics

Service providers — offer training and after-sales support

Regulators/standards bodies — set guidelines for PGD practices

Recent Industry Insights

Analyst Overview

Table of Contents